IMDx's GraftAssure Dx: Progress & Revenue

IMDx makes significant strides with GraftAssure Dx, submitting it to the FDA in March. Theyve received positive feedback and are preparing for U.S. orders later this year. Market research supports their high-value, high-margin strategy. Overseas, theyre expanding in Switzerland, Southeast Asia, and eyeing UK and EU approvals. Clinicians are increasingly interested in the GALACTIC registry, and theyve secured their first clinical trial deal. Financially, theyve covered costs and expect lower cash burn in the second half. Pricing talks suggest high margins, with heart transplant expansion already planned. Europe shows strong demand, and U.S. reimbursement gives them an edge. Theyre rapidly de-risking and moving towards their first revenue wave. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/cac93f0765de6f19